Bryn Mawr Capital Management LLC Acquires 33,850 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Bryn Mawr Capital Management LLC lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1,871.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,659 shares of the medical research company’s stock after buying an additional 33,850 shares during the quarter. Bryn Mawr Capital Management LLC owned about 0.07% of Charles River Laboratories International worth $6,583,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of CRL. Creative Planning grew its holdings in Charles River Laboratories International by 4.0% during the 3rd quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock worth $920,000 after acquiring an additional 180 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Charles River Laboratories International by 2.5% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 5,818 shares of the medical research company’s stock worth $1,146,000 after purchasing an additional 141 shares during the period. Blue Trust Inc. grew its stake in shares of Charles River Laboratories International by 28.6% during the third quarter. Blue Trust Inc. now owns 1,877 shares of the medical research company’s stock worth $388,000 after purchasing an additional 418 shares during the period. Raymond James & Associates increased its holdings in Charles River Laboratories International by 0.4% in the third quarter. Raymond James & Associates now owns 249,037 shares of the medical research company’s stock valued at $49,053,000 after purchasing an additional 925 shares during the last quarter. Finally, OLD National Bancorp IN lifted its stake in Charles River Laboratories International by 3.1% in the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after buying an additional 59 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Up 6.9 %

NYSE:CRL opened at $165.00 on Thursday. The stock has a 50-day simple moving average of $174.02 and a 200 day simple moving average of $188.99. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $275.00. The company has a market cap of $8.44 billion, a PE ratio of 20.65, a PEG ratio of 5.91 and a beta of 1.37. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period last year, the business earned $2.46 EPS. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on CRL shares. UBS Group reaffirmed a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Barclays reduced their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday. TD Cowen upped their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Finally, Morgan Stanley reduced their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $197.64.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).